Welcome to our dedicated page for Pharmather Holdings news (Ticker: PHRRF), a resource for investors and traders seeking the latest updates and insights on Pharmather Holdings stock.
PharmaTher Holdings Ltd. develops specialty pharmaceutical platforms centered on microneedle drug delivery. Company updates focus on PharmaPatch™ product programs for ketamine, psychedelics, GLP-1 drugs and therapeutic peptides, along with PatchPrint™, its automated tabletop microneedle patch 3D printer designed to support end-to-end patch manufacturing.
Recurring news themes include U.S. patent applications for patch manufacturing and peptide formulations, expansion of the PharmaPatch™ platform into new drug categories, regulatory and policy developments affecting ketamine, psychedelics and peptides, and the company's retained economic participation tied to its previously approved and sold U.S. generic ketamine ANDA.
PharmaTher (OTCQB: PHRRF) announced PERSONALIZ3D™, a personalized medicine platform that combines telehealth, pharmaceutical 3D printing and pharmacy fulfillment into an integrated ecosystem. The model centers on two business units: a telehealth platform linking patients with independent licensed healthcare providers and a North American network of pharmacy-based 3D-printing systems for compounded medicines.
PERSONALIZ3D™ will initially focus on peptides and other compounded prescriptions, offering customizable doses, combinations and dosage forms via digitally controlled pharmacy workflows with quality assurance and traceability. PharmaTher plans three rollout stages: establishing a Section 503A “Center of Excellence” pharmacy, launching a controlled telehealth program, and scaling via pharmaceutical 3D-printing system placements with U.S. Section 503A and Canadian compound pharmacies. The platform builds on PharmaTher’s collaboration with Craft Health’s CraftMake™ system and is structured to generate multiple recurring revenue streams.
PharmaTher (OTCQB: PHRRF) announced a collaboration with Craft Health to evaluate Craft Health's CraftMake™ GMP-ready pharmaceutical 3D printing platform for PharmaTher's Personaliz3D Peptides™ partner ecosystem. The parties will develop and test novel peptide formulations, personalized doses, combination products, controlled-release designs and differentiated dosage forms.
According to PharmaTher, the work will assess multiple peptides, including BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, which were recently recommended by the FDA Pharmacy Compounding Advisory Committee for inclusion on the Section 503A Bulks List. The collaboration also contemplates a potential broader commercial relationship to deploy CraftMake™ with qualified Section 503A compounding pharmacies, combining PharmaTher's personalized peptide strategy with Craft Health's 3D printing hardware, software and printable formulations.
PharmaTher (CSE: PHRM, OTCQB: PHRRF) launched Personaliz3D Peptides™, a new division focused on personalized peptide therapies using 3D printing, artificial intelligence, telemedicine and qualified 503A compounding pharmacies. The division aims to integrate physician oversight, patient assessment and GMP-aligned manufacturing to enable patient-specific dosing, combination peptide formulations and alternative delivery formats such as tablets, gummies, oral films, gels, chews, suppositories and patches.
The launch follows recent positive, but non-binding, FDA Pharmacy Compounding Advisory Committee recommendations to add several peptides, including BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, to the Section 503A Bulks List. PharmaTher plans a three-part strategy—Connect, Personalize and Deliver—centered on a new telemedicine platform at PersonalizedPeptidesRx.com, proprietary formulations, 3D printing systems, AI-assisted tools and a partnership-driven commercialization model with pharmacies, healthcare providers, researchers and pharmaceutical companies.
PharmaTher (CSE: PHRM, OTCQB: PHRRF) announced a collaboration with KetaMist inventor Dr. Curtis W. Cassidy to pursue U.S. FDA approval of the needle-free, patient-controlled ketamine platform for treatment-resistant depression and other conditions where ketamine has shown benefit.
KetaMist has reportedly been used in over 9,000 patient treatments, providing real-world experience that PharmaTher believes may support an efficient, potentially expedited FDA development strategy. PharmaTher will leverage its prior FDA-approved ketamine ANDA experience, despite having sold that ANDA in 2025, to guide regulatory, CMC and analytical aspects.
The collaboration includes a one-year evaluation period for PharmaTher to assess KetaMist and potentially negotiate further development and commercialization agreements. Near-term priorities include preparing an FDA meeting package, defining data and clinical requirements for a possible NDA, and evaluating the role of existing real-world data, while noting there is no assurance of FDA acceptance or approval.
PharmaTher (OTCQB: PHRRF) announced a strategic focus on personalized medicines in peptides and psychedelics, built around its MEDBOTX™ robotic 3D-printing and AI formulation platform. The company aims to enable patient-specific dosing, controlled-release profiles, and multiple dosage formats such as tablets, films, gels, and patches.
PharmaTher highlights upcoming FDA Pharmacy Compounding Advisory Committee discussions on peptide bulk substances and recent FDA guidance on psychedelic clinical studies as potential enablers of compliant development. The company plans a capital‑efficient commercialization model including proprietary formulations, partnerships with 503A pharmacies, hospitals, research institutions, pharma and biotech firms, and supplying MEDBOTX™ systems and consumables.
PharmaTher (OTCQB:PHRRF) is shifting its core platform from PatchPrint to MEDBOTX, a robotic 3D printing system for personalized medicines, peptides and advanced dose formats. MEDBOTX targets point-of-care and small-batch manufacturing in hospitals, compounding pharmacies, research institutions and partner settings.
The company plans commercial readiness in summer–fall 2026, with a focus on regulated peptides, compounded pharmaceuticals, consumables-based recurring revenue and CDMO-style formulation services.
PharmaTher (OTCQB:PHRRF) announced that Sairiyo Therapeutics, 49% owned by PharmaTher, is advancing its patented oral cepharanthine formulation PD-001 as a potential candidate for Hantavirus-related diseases.
Independent research found cepharanthine inhibited Hantavirus pseudovirus infection in mice by about 92–94% at 45–180 mg/kg/day. PD-001 has Australian ethics approval for a first-in-human Phase 1 trial in healthy volunteers to assess safety and pharmacokinetics only. PharmaTher emphasizes PD-001 is not proven to treat or prevent Hantavirus or any infectious disease, and future development depends on Phase 1 results, further data, regulatory review, financing, and manufacturing readiness.
PharmaTher (OTCQB: PHRRF) says a U.S. executive order on accelerating treatments for serious mental illness (April 18, 2026) could create a more supportive regulatory backdrop for its ketamine programs. The company highlights its KetaVault partnership portal, a completed IND‑enabling PK/tolerability study for a ketamine microneedle patch, retained ketamine programs, and ongoing upside from a prior FDA‑approved ketamine ANDA sale that may generate more than US$25 million over time, subject to commercial performance.
PharmaTher (OTCQB: PHRRF) says its PatchPrint™ automated microneedle manufacturing platform and PharmaPatch™ product platform could benefit from two U.S. regulatory shifts: a presidential executive order accelerating psychedelic treatments and an FDA/HHS move to reclassify therapeutic peptides with an advisory meeting on July 23–24, 2026.
The company highlights completed IND‑enabling work for a ketamine patch, provisional U.S. patent filings for peptide candidates and PatchPrint™, and potential commercial pathways for compounding pharmacies and hospitals.
PharmaTher (OTCQB: PHRRF) supports a proposed U.S. peptide reclassification and links the potential policy change to increased commercial relevance for its PharmaPatch microneedle delivery and PatchPrint manufacturing platform.
The company notes the FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee agenda lists BPC-157, KPV and TB-500—peptides already on PharmaTher's roadmap—and cites a provisional patent filed April 13, 2026 for stabilized peptide formulations for microneedle delivery.